ASCO 2018 | CAR T-cells in hemonc: where do we stand?
CAR T-cells represent an important step forward in the treatment of a variety of hematological malignancies. At the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Stephan Grupp, MD, PhD, of the Children’s Hospital of Philadelphia, Philadelphia, PA, gave an overview of the current state of CAR T-cell therapy in the clinic and research across several blood cancer types. He discusses tisagenlecleucel in acute lymphoblastic leukemia (ALL) and lymphoma. In both diseases, he highlights the potential for using these therapies outside of the currently recommended criteria, for example in the frontline setting or in ultra high-risk disease.
Get great new content delivered to your inboxSign up